Literature DB >> 19383364

Biomarkers in oncology drug development.

Darren R Hodgson1, Robin D Whittaker, Athula Herath, Dereck Amakye, Glen Clack.   

Abstract

Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. For those drugs taken forward, biomarker measurements may also help choose the appropriate dose, schedule and patient population. In this review we discuss the intrinsic properties of biological sample based efficacy measurements and how these relate to their implementation in oncology drug development by way of points to consider and examples.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19383364      PMCID： PMC5527864          DOI： 10.1016/j.molonc.2008.12.002

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  32 in total

Review 1.  Preoperative models to evaluate endocrine strategies for breast cancer.

Authors:  Mitch Dowsett
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

Review 2.  Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Authors:  Christopher J Weir; Rosalind J Walley
Journal:  Stat Med       Date:  2006-01-30       Impact factor: 2.373

3.  Surrogate endpoints: wishful thinking or reality?

Authors:  Stuart G Baker
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

Review 4.  The use of genomics in clinical trial design.

Authors:  Richard Simon
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

5.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

Review 6.  Circulating nucleic acids (CNAs) and cancer--a survey.

Authors:  M Fleischhacker; B Schmidt
Journal:  Biochim Biophys Acta       Date:  2006-10-07

7.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

8.  Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Authors:  Sunil S Badve; Frederick L Baehner; Robert P Gray; Barrett H Childs; Tara Maddala; Mei-Lan Liu; Steve C Rowley; Steven Shak; Edith A Perez; Edith D Perez; Lawrence J Shulman; Silvana Martino; Nancy E Davidson; George W Sledge; Lori J Goldstein; Joseph A Sparano
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

9.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Authors:  Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544

10.  The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.

Authors:  Susan J Cleator; Trevor J Powles; Tim Dexter; Laura Fulford; Alan Mackay; Ian E Smith; Haukur Valgeirsson; Alan Ashworth; Mitch Dowsett
Journal:  Breast Cancer Res       Date:  2006-06-21       Impact factor: 6.466
View more
  8 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

Review 2.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

Review 3.  Biomarkers in oncology drug development.

Authors:  Darren R Hodgson; Robin D Whittaker; Athula Herath; Dereck Amakye; Glen Clack
Journal:  Mol Oncol       Date:  2008-12-11       Impact factor: 6.603

Review 4.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

5.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Authors:  Jonathan R Dry; Sandra Pavey; Christine A Pratilas; Chris Harbron; Sarah Runswick; Darren Hodgson; Christine Chresta; Rose McCormack; Natalie Byrne; Mark Cockerill; Alexander Graham; Garry Beran; Andrew Cassidy; Carolyn Haggerty; Helen Brown; Gillian Ellison; Judy Dering; Barry S Taylor; Mitchell Stark; Vanessa Bonazzi; Sugandha Ravishankar; Leisl Packer; Feng Xing; David B Solit; Richard S Finn; Neal Rosen; Nicholas K Hayward; Tim French; Paul D Smith
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

6.  Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Daniel M Lerman; Michael J Monument; Elizabeth McIlvaine; Xiao-qiong Liu; Dali Huang; Laura Monovich; Natalie Beeler; Richard G Gorlick; Neyssa M Marina; Richard B Womer; Julia A Bridge; Mark D Krailo; R Lor Randall; Stephen L Lessnick
Journal:  Pediatr Blood Cancer       Date:  2014-12-02       Impact factor: 3.167

7.  Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.

Authors:  Julio E Celis; Teresa Cabezón; José M A Moreira; Pavel Gromov; Irina Gromova; Vera Timmermans-Wielenga; Takuji Iwase; Futoshi Akiyama; Naoko Honma; Fritz Rank
Journal:  Mol Oncol       Date:  2009-02-03       Impact factor: 6.603

8.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.